Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 211198, China.
Department of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 211198, China.
Curr Pharm Des. 2021;27(25):2861-2871. doi: 10.2174/1381612827666210322125054.
Chronic prostatitis/chronic pelvic pain syndrome type III is related to irritative voiding, sexual dysfunction, and pelvic pain. Chronic prostatitis/chronic pelvic pain syndrome weakens the quality of life and poses adverse psychological effects on the patients. A wide range of treatments, including botulinum neurotoxins, anti-inflammatories, alpha-blockers, phytotherapy, 5α-reductase inhibitors, phosphodiesterase type 4 inhibitor, phosphodiesterase type 5 inhibitor, monoclonal antibody, anticholinergics, gabapentin, pregabalin is used clinically. These therapies emphasize easing the symptoms in specific areas without curing the fundamental cause where the outcome of the treatment is not completely satisfactory. This review article explains the recent pharmacological treatments of chronic prostatitis/chronic pelvic pain syndrome in detail and offers a future perspective to treat this condition.
慢性前列腺炎/慢性骨盆疼痛综合征 III 型与刺激性排尿、性功能障碍和骨盆疼痛有关。慢性前列腺炎/慢性骨盆疼痛综合征会降低生活质量,并对患者造成不良的心理影响。目前有多种治疗方法,包括肉毒杆菌神经毒素、抗炎药、α-受体阻滞剂、植物疗法、5α-还原酶抑制剂、磷酸二酯酶 4 抑制剂、磷酸二酯酶 5 抑制剂、单克隆抗体、抗胆碱能药、加巴喷丁、普瑞巴林等。这些治疗方法侧重于缓解特定区域的症状,而不是治愈根本原因,因此治疗效果并不完全令人满意。本文详细阐述了慢性前列腺炎/慢性骨盆疼痛综合征的近期药理学治疗方法,并对该疾病的未来治疗方法进行了展望。